XENON PHARMACEUTICALS INC. Preferred Stock, Value, Issued
XENON PHARMACEUTICALS INC. (XENE) had Preferred Stock, Value, Issued of $0 as of 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:PreferredStockValue · last filed 2023-03-01
- 2022-09-30: Preferred Stock, Value, Issued $0.00.
- 2022-06-30: Preferred Stock, Value, Issued $0.00.
- 2022-03-31: Preferred Stock, Value, Issued $0.00.
- 2021-12-31: Preferred Stock, Value, Issued $7.73M.
| Period end | Preferred Stock, Value, Issued |
|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 |
| 2021-12-31 | $7.73M 10-K · filed 2023-03-01 |
| 2021-09-30 | $7.73M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $7.73M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $7.73M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $7.73M 10-K · filed 2022-03-01 |
| 2020-09-30 | $7.73M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $7.73M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $7.73M 10-Q/A · filed 2020-05-26 |
| 2019-12-31 | $7.73M 10-K · filed 2021-03-01 |
| 2019-09-30 | $7.73M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $7.73M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $7.73M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $7.73M 10-K · filed 2020-03-09 |
| 2018-09-30 | $11.93M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $21.82M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $21.82M 10-Q · filed 2018-05-08 |
| 2014-09-30 | $102.49M 10-Q · filed 2014-12-15 |
| 2013-12-31 | $102.49M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |